Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study
Rattachement africain : be, es, fi, ro. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Investigational and marketed drugs for the treatment of multiple myeloma (MM) are associated with a range of characteristics and uncertainties regarding long term side-effects and efficacy. This raises questions about what matters most to patients living with this disease. This study aimed to understand which characteristics MM patients find most important, and hence should be included as attributes and levels in a subsequent quantitative preference survey among MM patients. Methods: This qualitative study involved: (i) a scoping literature review, (ii) discussions with MM patients (n = 24) in Belgium, Finland, Romania, and Spain using Nominal Group Technique, (iii) a qualitative thematic analysis including multi-stakeholder discussions. Results: MM patients voiced significant expectations and hopes that treatments would extend their lives and reduce their cancer signs and symptoms. Participants however raised concerns about life-threatening side-effects that could cause permanent organ damage. Bone fractures and debilitating neuropathic effects (such as chronic tingling sensations) were highlighted as major issues reducing patients' independence and mobility. Patients discussed the negative impact of the following symptoms and side-effects on their daily activities: thinking problems, increased susceptibility to infections, reduced energy, pain, emotional problems, and vision problems. MM patients were concerned with uncertainties regarding the durability of positive treatment outcomes, and the cause, severity, and duration of their symptoms and side-effects. Patients feared short-term positive treatment responses complicated by permanent, severe side-effects and symptoms. Conclusions: This study gained an in-depth understanding of the treatment and disease-related characteristics and types of attribute levels (severity, duration) that are most important to MM patients. Results from this study argue in favor of MM drug development and individual treatment decision-making that focuses not only on extending patients' lives but also on addressing those symptoms and side-effects that significantly impact MM patients' quality of life. This study underscores a need for transparent communication toward MM patients about MM treatment outcomes and uncertainties regarding their long-term efficacy and safety. Finally, this study may help drug developers and decision-makers understand which treatment outcomes and uncertainties are most important to MM patients and therefore should be incorporated in MM drug development, evaluation, and clinical practice.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study
- Date Crossref
- 06/07/2021
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
KU Leuven pays non établi dans la noticeUniversité ou école supérieure
-
European Federation of Allergy and Airways Diseases Patients Associations pays non établi dans la noticeOrganisation à but non lucratif
-
Hospital de Sant Joan Despí Moisès Broggi pays non établi dans la noticeÉtablissement de santé
-
University of Helsinki pays non établi dans la noticeUniversité ou école supérieure
-
Helsinki University Hospital Department of Hematology pays non établi dans la noticeÉtablissement de santé
-
Carol Davila University of Medicine and Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
Institutul Clinic Fundeni pays non établi dans la noticeÉtablissement de santé
-
Cancer Society of Finland pays non établi dans la noticeInstitution
-
Université Libre de Bruxelles Institute for Interdisciplinary Innovation in Healthcare (I3h) pays non établi dans la noticeUniversité ou école supérieure
-
Department of Pharmaceutical and Pharmacological Sciences pays non établi dans la noticeInstitution
-
Myeloma Patients Europe pays non établi dans la noticeInstitution
-
H. Moises Broggi/ICO-Hospitalet Department of Haematology pays non établi dans la noticeÉtablissement de santé
KU Leuven, European Federation of Allergy and Airways Diseases Patients Associations et Hospital de Sant Joan Despí Moisès Broggi, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.